Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,637
Award facts
- Contract value 100% obligated
- $38,636.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $38,636.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml syringes. The award, issued on January 6, 2026, with an ultimate completion date of January 7, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and a completion date of December 31, 2036.
Nucala, an immunosuppressant biologic agent, is one of numerous specialty pharmaceuticals within DMS Pharmaceutical Group's comprehensive product portfolio supplied to support Department of Defense healthcare operations globally. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide recurring pharmaceutical and medical supply solutions to military healthcare facilities worldwide. DMS Pharmaceutical Group's demonstrated performance across multiple delivery orders and its established position as a critical supplier within the federal pharmaceutical supply chain underscore its capability to fulfill the specialized medical requirements of the military medical system with no identified subcontractors.
Quick answers
Who was awarded contract SPE2DR26FFBU9?
SPE2DR26FFBU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FFBU9 worth?
The government has obligated $38,637 on SPE2DR26FFBU9.
Is contract SPE2DR26FFBU9 an order under another contract?
Yes. SPE2DR26FFBU9 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBU9 competed?
The extent of competition for SPE2DR26FFBU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award